Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Bays

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|September 11, 2008
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemiaHarold Bays, Aditi Sapre, William Taggart, et al.
Current Treatment Options in Cardiovascular Medicine|September 1, 2007
Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease riskHarold Bays, Helena W Rodbard, Alan Bruce Schorr, et al.
International Journal of Hypertension|May 9, 2013
Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled TrialHarold Bays, Pingjin Gao, Birgit Völker, et al.
Metabolic Syndrome and Related Disorders|March 10, 2012
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitusHarold Bays, Hilde Giezek, James M McKenney, et al.
Circulation|April 27, 2011
Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemiaEvan A Stein, Harold Bays, Dennis O'Brien, et al.
Journal of Clinical Lipidology|February 5, 2011
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemiaMichael H Davidson, Kevin C Maki, Harold Bays, et al.
Clinical Therapeutics|August 25, 2005
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled studyMichael H Davidson, Harold Bays, James Rhyne, et al.
Integrated Blood Pressure Control|May 3, 2013
Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trialDingliang Zhu, Harold Bays, Pingjin Gao, et al.
Clinical Therapeutics|June 22, 2012
Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trialDingliang L Zhu, Harold Bays, Pingjin Gao, et al.
Journal of Clinical Lipidology|June 16, 2015
Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trialsJames McKenney, Harold Bays, Gilbert Gleim, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|September 11, 2008
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemiaHarold Bays, Aditi Sapre, William Taggart, et al.
Current Treatment Options in Cardiovascular Medicine|September 1, 2007
Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease riskHarold Bays, Helena W Rodbard, Alan Bruce Schorr, et al.
International Journal of Hypertension|May 9, 2013
Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled TrialHarold Bays, Pingjin Gao, Birgit Völker, et al.
Metabolic Syndrome and Related Disorders|March 10, 2012
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitusHarold Bays, Hilde Giezek, James M McKenney, et al.
Circulation|April 27, 2011
Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemiaEvan A Stein, Harold Bays, Dennis O'Brien, et al.
Journal of Clinical Lipidology|February 5, 2011
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemiaMichael H Davidson, Kevin C Maki, Harold Bays, et al.
Clinical Therapeutics|August 25, 2005
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled studyMichael H Davidson, Harold Bays, James Rhyne, et al.
Integrated Blood Pressure Control|May 3, 2013
Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trialDingliang Zhu, Harold Bays, Pingjin Gao, et al.
Clinical Therapeutics|June 22, 2012
Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trialDingliang L Zhu, Harold Bays, Pingjin Gao, et al.
Journal of Clinical Lipidology|June 16, 2015
Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trialsJames McKenney, Harold Bays, Gilbert Gleim, et al.
Pageof 8